AN2 Net Income vs Net Income Per Share Analysis

ANTX Stock

USD 1.17 0.01 0.85%

AN2 Therapeutics financial indicator trend analysis is way more than just evaluating AN2 Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AN2 Therapeutics is a good investment. Please check the relationship between AN2 Therapeutics Net Income and its Net Income Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.

Net Income vs Net Income Per Share

Net Income vs Net Income Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AN2 Therapeutics Net Income account and Net Income Per Share. At this time, the significance of the direction appears to have totally related.

The correlation between AN2 Therapeutics' Net Income and Net Income Per Share is 0.99. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Net Income Per Share in the same time period over historical financial statements of AN2 Therapeutics, assuming nothing else is changed. The correlation between historical values of AN2 Therapeutics' Net Income and Net Income Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of AN2 Therapeutics are associated (or correlated) with its Net Income Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per Share has no effect on the direction of Net Income i.e., AN2 Therapeutics' Net Income and Net Income Per Share go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in AN2 Therapeutics financial statement analysis. It represents the amount of money remaining after all of AN2 Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Net Income Per Share

Most indicators from AN2 Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AN2 Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AN2 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy AN2 Stock please use our How to Invest in AN2 Therapeutics guide.At this time, AN2 Therapeutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 90.19 in 2025, whereas Issuance Of Capital Stock is likely to drop slightly above 65.6 M in 2025.

	2021	2022	2024	2025 (projected)
Interest Income	69K	1.4M	1.6M	1.6M
Net Interest Income	69K	1.4M	1.6M	1.6M

Interest Income Net Interest Income

AN2 Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Other Liab	Other Stockholder Equity	Net Invested Capital	Net Working Capital	Non Currrent Assets Other	Other Assets	Deferred Long Term Liab	Property Plant And Equipment Net	Non Current Liabilities Other	Short Term Debt
Total Assets		-0.81	0.98	0.98	0.9	0.9	-0.8	-0.98	1.0	0.82	1.0	0.84	0.05	1.0	0.26	1.0	-0.92	0.93	0.94	0.95	-0.9	-0.97	-0.72	-0.72	-0.72	-0.72
Short Long Term Debt Total	-0.81		-0.77	-0.78	-0.57	-0.61	0.75	0.83	-0.82	-0.74	-0.83	-0.59	-0.39	-0.83	-0.55	-0.83	0.87	-0.66	-0.69	-0.84	0.73	0.73	0.46	0.46	0.46	0.46
Other Current Liab	0.98	-0.77		1.0	0.92	0.9	-0.67	-0.97	0.98	0.7	0.96	0.89	-0.06	0.97	0.15	0.96	-0.83	0.95	0.96	0.88	-0.85	-0.98	-0.77	-0.77	-0.77	-0.77
Total Current Liabilities	0.98	-0.78	1.0		0.92	0.91	-0.71	-0.98	0.99	0.73	0.97	0.88	-0.05	0.98	0.17	0.97	-0.85	0.96	0.96	0.9	-0.87	-0.98	-0.76	-0.76	-0.76	-0.76
Total Stockholder Equity	0.9	-0.57	0.92	0.92		0.99	-0.7	-0.9	0.91	0.73	0.88	0.83	-0.4	0.89	-0.19	0.88	-0.7	0.99	0.99	0.81	-0.92	-0.97	-0.71	-0.71	-0.71	-0.71
Net Tangible Assets	0.9	-0.61	0.9	0.91	0.99		-0.77	-0.9	0.91	0.79	0.89	0.79	-0.38	0.9	-0.18	0.89	-0.73	0.99	0.99	0.83	-0.95	-0.96	-0.67	-0.67	-0.67	-0.67
Net Debt	-0.8	0.75	-0.67	-0.71	-0.7	-0.77		0.78	-0.81	-0.99	-0.85	-0.48	-0.1	-0.82	-0.25	-0.84	0.88	-0.7	-0.76	-0.88	0.92	0.74	0.34	0.34	0.34	0.34
Retained Earnings	-0.98	0.83	-0.97	-0.98	-0.9	-0.9	0.78		-0.98	-0.8	-0.98	-0.86	0.0	-0.98	-0.22	-0.98	0.91	-0.93	-0.95	-0.95	0.9	0.98	0.63	0.63	0.63	0.63
Accounts Payable	1.0	-0.82	0.98	0.99	0.91	0.91	-0.81	-0.98		0.83	1.0	0.83	0.02	1.0	0.23	1.0	-0.92	0.94	0.95	0.95	-0.92	-0.97	-0.71	-0.71	-0.71	-0.71
Cash	0.82	-0.74	0.7	0.73	0.73	0.79	-0.99	-0.8	0.83		0.86	0.57	0.06	0.84	0.22	0.86	-0.89	0.73	0.78	0.91	-0.93	-0.77	-0.36	-0.36	-0.36	-0.36
Cash And Short Term Investments	1.0	-0.83	0.96	0.97	0.88	0.89	-0.85	-0.98	1.0	0.86		0.8	0.08	1.0	0.28	1.0	-0.94	0.91	0.93	0.96	-0.92	-0.95	-0.69	-0.69	-0.69	-0.69
Common Stock Shares Outstanding	0.84	-0.59	0.89	0.88	0.83	0.79	-0.48	-0.86	0.83	0.57	0.8		-0.15	0.82	0.04	0.8	-0.71	0.85	0.84	0.81	-0.7	-0.87	-0.58	-0.58	-0.58	-0.58
Non Current Liabilities Total	0.05	-0.39	-0.06	-0.05	-0.4	-0.38	-0.1	0.0	0.02	0.06	0.08	-0.15		0.06	0.98	0.07	-0.34	-0.33	-0.28	0.14	0.19	0.18	0.12	0.12	0.12	0.12
Other Current Assets	1.0	-0.83	0.97	0.98	0.89	0.9	-0.82	-0.98	1.0	0.84	1.0	0.82	0.06		0.27	1.0	-0.93	0.92	0.94	0.95	-0.91	-0.96	-0.71	-0.71	-0.71	-0.71
Total Liab	0.26	-0.55	0.15	0.17	-0.19	-0.18	-0.25	-0.22	0.23	0.22	0.28	0.04	0.98	0.27		0.28	-0.52	-0.12	-0.07	0.33	-0.01	-0.03	-0.04	-0.04	-0.04	-0.04
Total Current Assets	1.0	-0.83	0.96	0.97	0.88	0.89	-0.84	-0.98	1.0	0.86	1.0	0.8	0.07	1.0	0.28		-0.94	0.91	0.93	0.96	-0.92	-0.95	-0.69	-0.69	-0.69	-0.69
Other Liab	-0.92	0.87	-0.83	-0.85	-0.7	-0.73	0.88	0.91	-0.92	-0.89	-0.94	-0.71	-0.34	-0.93	-0.52	-0.94		-0.74	-0.78	-0.97	0.83	0.82	0.48	0.48	0.48	0.48
Other Stockholder Equity	0.93	-0.66	0.95	0.96	0.99	0.99	-0.7	-0.93	0.94	0.73	0.91	0.85	-0.33	0.92	-0.12	0.91	-0.74		1.0	0.84	-0.92	-0.99	-0.73	-0.73	-0.73	-0.73
Net Invested Capital	0.94	-0.69	0.96	0.96	0.99	0.99	-0.76	-0.95	0.95	0.78	0.93	0.84	-0.28	0.94	-0.07	0.93	-0.78	1.0		0.87	-0.94	-0.99	-0.71	-0.71	-0.71	-0.71
Net Working Capital	0.95	-0.84	0.88	0.9	0.81	0.83	-0.88	-0.95	0.95	0.91	0.96	0.81	0.14	0.95	0.33	0.96	-0.97	0.84	0.87		-0.9	-0.9	-0.49	-0.49	-0.49	-0.49
Non Currrent Assets Other	-0.9	0.73	-0.85	-0.87	-0.92	-0.95	0.92	0.9	-0.92	-0.93	-0.92	-0.7	0.19	-0.91	-0.01	-0.92	0.83	-0.92	-0.94	-0.9		0.92	0.57	0.57	0.57	0.57
Other Assets	-0.97	0.73	-0.98	-0.98	-0.97	-0.96	0.74	0.98	-0.97	-0.77	-0.95	-0.87	0.18	-0.96	-0.03	-0.95	0.82	-0.99	-0.99	-0.9	0.92		0.69	0.69	0.69	0.69
Deferred Long Term Liab	-0.72	0.46	-0.77	-0.76	-0.71	-0.67	0.34	0.63	-0.71	-0.36	-0.69	-0.58	0.12	-0.71	-0.04	-0.69	0.48	-0.73	-0.71	-0.49	0.57	0.69		1.0	1.0	1.0
Property Plant And Equipment Net	-0.72	0.46	-0.77	-0.76	-0.71	-0.67	0.34	0.63	-0.71	-0.36	-0.69	-0.58	0.12	-0.71	-0.04	-0.69	0.48	-0.73	-0.71	-0.49	0.57	0.69	1.0		1.0	1.0
Non Current Liabilities Other	-0.72	0.46	-0.77	-0.76	-0.71	-0.67	0.34	0.63	-0.71	-0.36	-0.69	-0.58	0.12	-0.71	-0.04	-0.69	0.48	-0.73	-0.71	-0.49	0.57	0.69	1.0	1.0		1.0
Short Term Debt	-0.72	0.46	-0.77	-0.76	-0.71	-0.67	0.34	0.63	-0.71	-0.36	-0.69	-0.58	0.12	-0.71	-0.04	-0.69	0.48	-0.73	-0.71	-0.49	0.57	0.69	1.0	1.0	1.0

Click cells to compare fundamentals

AN2 Therapeutics Account Relationship Matchups

AN2 Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	4.2M	65.3M	102.6M	138.7M	159.6M	167.5M
Other Current Liab	1.3M	2.3M	5.0M	11.4M	13.1M	13.7M
Total Current Liabilities	1.5M	3.4M	7.2M	14.0M	16.1M	17.0M
Total Stockholder Equity	(20.3M)	(47.4M)	95.4M	124.7M	143.4M	150.6M
Net Debt	(4.1M)	(12.1M)	(27.2M)	(15.6M)	(14.1M)	(14.8M)
Retained Earnings	(20.3M)	(47.4M)	(89.7M)	(154.5M)	(139.0M)	(132.1M)
Accounts Payable	132K	1.1M	2.1M	2.7M	3.1M	3.2M
Cash	4.1M	12.1M	27.2M	15.6M	18.0M	14.2M
Cash And Short Term Investments	4.1M	58.6M	96.1M	107.3M	123.4M	129.6M
Liabilities And Stockholders Equity	4.2M	65.3M	102.6M	138.7M	159.6M	167.5M
Other Current Assets	164K	1.6M	2.6M	3.2M	3.7M	3.9M
Total Liab	24.6M	112.7M	7.2M	14.0M	16.1M	15.3M
Total Current Assets	4.2M	60.1M	98.6M	110.5M	127.1M	133.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for AN2 Stock Analysis

When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AN2 Net Income vs Net Income Per Share Analysis

Net Income vs Net Income Per Share

Net Income vs Net Income Per Share Correlation Analysis

Correlation Coefficient

Net Income

Net Income Per Share

AN2 Therapeutics fundamental ratios Correlations

AN2 Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AN2 Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for AN2 Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accounts Payable	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Accounts Payable

Other Assets	- 0.99	Net Invested Capital
Other Assets	- 0.99	Other Stockholder Equity
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Cash And Short Term Investments	- 0.98	Retained Earnings